Half of Moderna’s coronavirus vaccine owned by NIH | WHAT REALLY HAPPENED

Half of Moderna’s coronavirus vaccine owned by NIH

Axios and Public Citizen have obtained new documents suggesting that the National Institutes of Health (NIH) owns half of the key patent on Moderna’s up-and-coming vaccine for the Wuhan coronavirus (COVID-19).

Should the vaccine come to market, the NIH will reportedly collect half of the royalties associated with its distribution. At the same time, four NIH scientists have filed provisional patents on their own claiming to be “co-inventors” of the experimental jab.

Many people do not know this, but the current cap on royalties for agency scientists who help develop a vaccine is set at $150,000. This means that there is a financial incentive to attach one’s name to vaccine development, incentivizing the creation of potentially useless and dangerous new drugs.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA